Cargando…
MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders
Autor principal: | Palko, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232794/ http://dx.doi.org/10.1016/j.jval.2022.04.1309 |
Ejemplares similares
-
The Digital Scientist to be launched in the New Year
por: The Digital Scientist Team
Publicado: (2010) -
Cybersecurity features of digital medical devices: an analysis of FDA product summaries
por: Stern, Ariel Dora, et al.
Publicado: (2019) -
FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate
por: Watson, Anthony, et al.
Publicado: (2023) -
Building the new digital world: launch of the European Heart Journal - Digital Health
por: Cowie, Martin R
Publicado: (2020) -
Drug and Therapeutics Committee (DTC) evolvement and expanded scope in Ethiopia
por: Seyoum, Habtamu, et al.
Publicado: (2023)